Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Euro Surveill ; 26(46)2021 11.
Article in English | MEDLINE | ID: mdl-34794536

ABSTRACT

BackgroundInvasive infections caused by Staphylococcus aureus have high clinical and epidemiological relevance. It is therefore important to monitor the S. aureus trends using suitable methods.AimThe study aimed to describe the trends of bloodstream infections (BSI) caused by meticillin-resistant S. aureus (MRSA) and meticillin-susceptible S. aureus (MSSA) in the European Union (EU) and the European Economic Area (EEA).MethodsAnnual data on S. aureus BSI from 2005 to 2018 were obtained from the European Antimicrobial Resistance Surveillance Network (EARS-Net). Trends of BSI were assessed at the EU/EEA level by adjusting for blood culture set rate (number of blood culture sets per 1,000 days of hospitalisation) and stratification by patient characteristics.ResultsConsidering a fixed cohort of laboratories consistently reporting data over the entire study period, MRSA percentages among S. aureus BSI decreased from 30.2% in 2005 to 16.3% in 2018. Concurrently, the total number of BSI caused by S. aureus increased by 57%, MSSA BSI increased by 84% and MRSA BSI decreased by 31%. All these trends were statistically significant (p < 0.001).ConclusionsThe results indicate an increasing health burden of MSSA BSI in the EU/EEA despite a significant decrease in the MRSA percentage. These findings highlight the importance of monitoring antimicrobial resistance trends by assessing not only resistance percentages but also the incidence of infections. Further research is needed on the factors associated with the observed trends and on their attributable risk.


Subject(s)
Methicillin-Resistant Staphylococcus aureus , Sepsis , Staphylococcal Infections , European Union , Humans , Methicillin/pharmacology , Staphylococcal Infections/diagnosis , Staphylococcal Infections/drug therapy , Staphylococcal Infections/epidemiology , Staphylococcus aureus
2.
Euro Surveill ; 24(33)2019 Aug.
Article in English | MEDLINE | ID: mdl-31431208

ABSTRACT

BackgroundAntibiotic resistance, either intrinsic or acquired, is a major obstacle for treating bacterial infections.AimOur objective was to compare the country-specific species distribution of the four Gram-negative species Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter species and the proportions of selected acquired resistance traits within these species.MethodWe used data reported for 2016 to the European Antimicrobial Resistance Surveillance Network (EARS-Net) by 30 countries in the European Union and European Economic Area.ResultsThe country-specific species distribution varied considerably. While E. coli accounted for 31.9% to 81.0% (median: 69.0%) of all reported isolates, the two most common intrinsically resistant species P. aeruginosa and Acinetobacter spp. combined (PSEACI) accounted for 5.5% to 39.2% of isolates (median: 10.1%). Similarly, large national differences were noted for the percentages of acquired non-susceptibility to third-generation cephalosporins, carbapenems and fluoroquinolones. There was a strong positive rank correlation between the country-specific percentages of PSEACI and the percentages of non-susceptibility to the above antibiotics in all four species (rho > 0.75 for 10 of the 11 pairs of variables tested).ConclusionCountries with the highest proportion of P. aeruginosa and Acinetobacter spp. were also those where the rates of acquired non-susceptibility in all four studied species were highest. The differences are probably related to national differences in antibiotic consumption and infection prevention and control routines.


Subject(s)
Acinetobacter/drug effects , Anti-Bacterial Agents/pharmacology , Bacteremia/drug therapy , Escherichia coli/drug effects , Klebsiella pneumoniae/drug effects , Pseudomonas aeruginosa/drug effects , Bacteremia/epidemiology , Carbapenems/pharmacology , Cephalosporins/pharmacology , Drug Resistance, Bacterial/drug effects , Europe/epidemiology , European Union , Fluoroquinolones/pharmacology , Gram-Negative Bacteria/drug effects , Gram-Negative Bacterial Infections/drug therapy , Gram-Negative Bacterial Infections/epidemiology , Humans , Microbial Sensitivity Tests , Sentinel Surveillance
3.
Emerg Infect Dis ; 14(11): 1722-30, 2008 Nov.
Article in English | MEDLINE | ID: mdl-18976555

ABSTRACT

Our study confronts the use of antimicrobial agents in ambulatory care with the resistance trends of 2 major pathogens, Streptococcus pneumoniae and Escherichia coli, in 21 European countries in 2000-2005 and explores whether the notion that antimicrobial drug use determines resistance can be supported by surveillance data at national aggregation levels. The data obtained from the European Surveillance of Antimicrobial Consumption and the European Antimicrobial Resistance Surveillance System suggest that variation of consumption coincides with the occurrence of resistance at the country level. Linear regression analysis showed that the association between antimicrobial drug use and resistance was specific and robust for 2 of 3 compound pathogen combinations, stable over time, but not sensitive enough to explain all of the observed variations. Ecologic studies based on routine surveillance data indicate a relation between use and resistance and support interventions designed to reduce antimicrobial drug consumption at a national level in Europe.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Drug Resistance, Bacterial , Escherichia coli Infections/drug therapy , Escherichia coli/drug effects , Pneumococcal Infections/drug therapy , Streptococcus pneumoniae/drug effects , Ambulatory Care , Drug Utilization/statistics & numerical data , Escherichia coli/isolation & purification , Escherichia coli Infections/epidemiology , Europe/epidemiology , Hospitals , Humans , Linear Models , Pneumococcal Infections/epidemiology , Product Surveillance, Postmarketing , Retrospective Studies , Streptococcus pneumoniae/isolation & purification
4.
PLoS One ; 9(1): e86634, 2014.
Article in English | MEDLINE | ID: mdl-24489755

ABSTRACT

BACKGROUND: Complicated urinary tract infections (c-UTIs) are among the most common nosocomial infections and a substantial part of the antimicrobial agents used in hospitals is for the treatment of c-UTIs. Data from surveillance can be used to guide the empirical treatment choices of clinicians when treating c-UTIs. We therefore used nation-wide surveillance data to evaluate antimicrobial coverage of agents for the treatment of c-UTI in the Netherlands. METHODS: We included the first isolate per patient of urine samples of hospitalised patients collected by the Infectious Disease Surveillance Information System for Antibiotic Resistance (ISIS-AR) in 2012, and determined the probability of inadequate coverage for antimicrobial agents based on species distribution and susceptibility. Analyses were repeated for various patient groups and hospital settings. RESULTS: The most prevalent bacteria in 27,922 isolates of 23,357 patients were Escherichia coli (47%), Enterococcus spp. (14%), Proteus mirabilis (8%), and Klebsiella pneumoniae (7%). For all species combined, the probability of inadequate coverage was <5% for amoxicillin or amoxicillin-clavulanic acid combined with gentamicin and the carbapenems. When including gram-negative bacteria only, the probability of inadequate coverage was 4.0%, 2.7%, 2.3% and 1.7%, respectively, for amoxicillin, amoxicillin-clavulanic acid, a second or a third generation cephalosporin in combination with gentamicin, and the carbapenems (0.4%). There were only small variations in results among different patient groups and hospital settings. CONCLUSIONS: When excluding Enterococcus spp., considered as less virulent, and the carbapenems, considered as last-resort drugs, empirical treatment for c-UTI with the best chance of adequate coverage are one of the studied beta-lactam-gentamicin combinations. This study demonstrates the applicability of routine surveillance data for up-to-date clinical practice guidelines on empirical antimicrobial therapy, essential in patient care given the evolving bacterial susceptibility.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Drug Resistance, Microbial , Epidemiological Monitoring , Health Planning Guidelines , Urinary Tract Infections/complications , Urinary Tract Infections/drug therapy , Anti-Bacterial Agents/pharmacology , Bacteria/drug effects , Bacteria/isolation & purification , Drug Resistance, Microbial/drug effects , Female , Hospitals/statistics & numerical data , Humans , Male , Microbial Sensitivity Tests , Netherlands/epidemiology , Probability , Urinary Tract Infections/epidemiology , Urinary Tract Infections/microbiology
5.
PLoS One ; 8(8): e73096, 2013.
Article in English | MEDLINE | ID: mdl-24009733

ABSTRACT

Methicillin-resistant Staphylococcus aureus (MRSA) is a worldwide problem in both hospitals and communities all over the world. In 2003, a new MRSA clade emerged with a reservoir in pigs and veal calves: livestock-associated MRSA (LA-MRSA). We wanted to estimate the incidence of bacteraemias due to LA-MRSA using national surveillance data from 2009 in the Netherlands. We found a low incidence of LA-MRSA and MRSA bacteraemia episodes, compared to bacteraemias caused by all S. aureus (0.04, 0.18 and 19.3 episodes of bacteraemia per 100,000 inhabitants per year, respectively). LA-MRSA and MRSA were uncommon compared to numbers from other countries as well. MRSA in general and LA-MRSA in specific does not appear to be a public health problem in the Netherlands now. The low incidence of LA-MRSA bacteraemia episodes may best be explained by differences in the populations affected by LA-MRSA versus other MRSA. However, reduced virulence of the strain involved, and the effectiveness of the search and destroy policy might play a role as well.


Subject(s)
Bacteremia/epidemiology , Methicillin-Resistant Staphylococcus aureus , Staphylococcal Infections/epidemiology , Adolescent , Adult , Aged , Aged, 80 and over , Animals , Carrier State/epidemiology , Child , Child, Preschool , Female , Humans , Incidence , Infant , Infant, Newborn , Livestock/microbiology , Male , Methicillin-Resistant Staphylococcus aureus/classification , Methicillin-Resistant Staphylococcus aureus/genetics , Methicillin-Resistant Staphylococcus aureus/isolation & purification , Middle Aged , Netherlands/epidemiology , Young Adult
6.
PLoS One ; 7(8): e42787, 2012.
Article in English | MEDLINE | ID: mdl-22880109

ABSTRACT

BACKGROUND: We describe the impact of methicillin-resistant Staphylococcus aureus (MRSA) in two neighbouring regions in Europe with a comparable population size, North Rhine-Westphalia (NRW) in Germany and the Netherlands. METHODOLOGY/PRINCIPAL FINDINGS: We compared the occurrence of MRSA in blood cultures from surveillance systems. In the Netherlands in 2009, 14 of 1,510 (0.9%) Staphylococcus aureus bacteraemia episodes under surveillance were MRSA. Extrapolation using the number of clinical admissions results in a total of 29 MRSA bacteraemia episodes in the Netherlands or 1.8 episodes per 1,000,000 inhabitants. In 2010 in NRW, 1,029 MRSA bacteraemias were reported, resulting in 57.6 episodes of MRSA bacteraemia per 1,000,000 inhabitants: a 32-fold higher incidence than in the Netherlands. CONCLUSION/SIGNIFICANCE: Based on an estimated attributable mortality of 15%, the Dutch approach would save approximately 150 lives per year by the prevention of bacteraemia only.


Subject(s)
Bacteremia/epidemiology , Bacteremia/microbiology , Methicillin-Resistant Staphylococcus aureus/physiology , Aged , Cross-Sectional Studies , Geography , Germany/epidemiology , Humans , Middle Aged , Netherlands/epidemiology
7.
J Antimicrob Chemother ; 60(6): 1310-5, 2007 Dec.
Article in English | MEDLINE | ID: mdl-17913724

ABSTRACT

OBJECTIVES: Efforts aimed at curtailing the ever increasing spread of methicillin-resistant Staphylococcus aureus (MRSA) require effective information of its epidemiology. However, knowledge about the situation in southern and eastern countries of the Mediterranean is incomplete since reports have been sporadic and difficult to compare. METHODS: Over a 36 month period from 2003 to 2005, the ARMed project collected more than 5000 susceptibility test results of invasive isolates of S. aureus from blood cultures routinely processed within participating laboratories servicing 62 hospitals situated in Algeria, Cyprus, Egypt, Jordan, Lebanon, Malta, Morocco, Tunisia and Turkey. RESULTS: Overall, the median MRSA proportion was 39% (interquartile range: 27.1% to 51.1%). The highest proportions of MRSA were reported by Jordan, Egypt and Cyprus, where more than 50% of the invasive isolates were methicillin-resistant. Considerable variation was identified in the proportion of MRSA in hospitals within the same country. CONCLUSIONS: It appears that most of the countries in the Mediterranean region are experiencing a surge in MRSA infections. This requires a greater focus to identify relevant drivers of resistance and implement effective practices in order to address them, especially improved infection control and antibiotic consumption practices.


Subject(s)
Methicillin Resistance , Population Surveillance/methods , Staphylococcal Infections/epidemiology , Staphylococcus aureus/drug effects , Anti-Bacterial Agents/pharmacology , Blood/microbiology , Culture Media , Humans , Mediterranean Region/epidemiology , Microbial Sensitivity Tests , Prevalence , Staphylococcal Infections/microbiology , Staphylococcus aureus/isolation & purification
8.
J Antimicrob Chemother ; 54(6): 1045-50, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15531598

ABSTRACT

OBJECTIVES: To forecast trends in resistance to penicillin and erythromycin among Streptococcus pneumoniae in Europe. METHODS: Since 1999, the European Antimicrobial Resistance Surveillance System (EARSS) has collected routine antimicrobial susceptibility test results of S. pneumoniae. To observe and predict changes of reduced susceptibility over time, we used a multinomial logistic regression model. RESULTS: Large variations in penicillin and erythromycin non-susceptibility were observed between countries, and reduced susceptibility to erythromycin (17%) has become more frequent than reduced susceptibility to penicillin (10%) in Europe overall. An overall decrease in single penicillin non-susceptibility, but an increase in dual non-susceptibility was observed, indicating a shift of single penicillin to combined non-susceptibility with erythromycin. By 2006, the proportion of single erythromycin and dual non-susceptibility could increase to as much as 20.4% and 8.9%, respectively. CONCLUSIONS: Our results indicate that appropriately dosed beta-lactams for empirical therapy are still the treatment of choice, and that macrolides should be used with prudence.


Subject(s)
Anti-Bacterial Agents/pharmacology , Drug Resistance, Bacterial , Erythromycin/pharmacology , Penicillin Resistance , Pneumococcal Infections/epidemiology , Streptococcus pneumoniae/drug effects , Adolescent , Adult , Aged , Anti-Bacterial Agents/therapeutic use , Child , Child, Preschool , Europe/epidemiology , Female , Humans , Logistic Models , Male , Microbial Sensitivity Tests , Middle Aged , Penicillins/pharmacology , Penicillins/therapeutic use , Pneumococcal Infections/microbiology , Population Surveillance
9.
Emerg Infect Dis ; 10(9): 1627-34, 2004 Sep.
Article in English | MEDLINE | ID: mdl-15498166

ABSTRACT

We explored the variation in proportions of methicillin-resistant Staphylococcus aureus (MRSA) between and within countries participating in the European Antimicrobial Resistance Surveillance System and temporal trends in its occurrence. This system collects routine antimicrobial susceptibility tests for S. aureus. We examined data collected from January 1999 through December 2002 (50,759 isolates from 495 hospitals in 26 countries). MRSA prevalence varied almost 100-fold, from <1% in northern Europe to >40% in southern and western Europe. MRSA proportions significantly increased in Belgium, Germany, Ireland, the Netherlands, and the United Kingdom, and decreased in Slovenia. Within countries, MRSA proportions varied between hospitals with highest variance in countries with a prevalence of 5% to 20%. The observed trends should stimulate initiatives to control MRSA at national, regional, and hospital levels. The large differences between hospitals indicate that efforts may be most effective at regional and hospital levels.


Subject(s)
Methicillin Resistance , Staphylococcal Infections/epidemiology , Staphylococcus aureus/drug effects , Europe/epidemiology , Humans , International Cooperation , Population Surveillance , Prevalence , Quality Assurance, Health Care , Staphylococcal Infections/microbiology
SELECTION OF CITATIONS
SEARCH DETAIL